18 F-Fluorodeoxyglucose (FDG) positron-emission tomography/ computed tomography (PET/CT) was recently introduced as a new tool for the diagnosis of prosthetic heart valve endocarditis (PVE). Previous studies reporting a modest diagnostic accuracy may have been hampered by unstandardized image acquisition and assessment, and several confounders, as well. The aim of this study was to improve the diagnostic performance of FDG PET/CT in patients in whom PVE was suspected by identifying and excluding possible confounders, using both visual and standardized quantitative assessments.
F-fluorodeoxyglucose (FDG) positron-emission tomography (PET)/computed tomography (CT) in PVE. 6, 7 FDG PET/CT aids in the diagnosis of both intracardiac and extracardiac infectious foci by functional visualization of inflammation, even before structural damage occurs. 7 However, FDG PET/CT findings have been reported to be influenced by several confounders such as myocardial FDG uptake, low inflammatory activity (eg, attributable to prolonged antibiotic therapy), prior use of surgical adhesives, and recent valve implantation. 8, 9 The first 3 possible confounders can be mitigated with adequate patient preparation, timely implementation of FDG PET/ CT in the diagnostic workup, and evaluation of the surgical report, 10 whereas evidence for the influence of recent valve implantation is scarce and inconsistent. 11 Besides a visual evaluation, FDG uptake can also be measured (semi)quantitatively, and potential cutoffs for the maximum measured intensity around a PV (standardized uptake value [SUV] max ), and target-to-background ratios (SUV ratio ), as well, have been reported. 12, 13 However, these reported cutoffs vary widely because of differences in calibration between scanners, and measurement and reconstruction techniques, as well. 10, [12] [13] [14] [15] Therefore, the European Association of Nuclear Medicine Research Ltd (EARL) has provided a standardized calibration and reconstruction method that is currently applied in >150 centers in Europe. 16 The aim of this study was to investigate the diagnostic performance of FDG PET/CT in a large multicenter cohort of patients in whom PVE was suspected by identifying and subsequently excluding potential confounders using both visual and EARL-standardized quantitative assessments. In addition, a cohort of patients with PVs but without suspicion of PVE, who underwent PET/ CT imaging for other (ie, oncological) indications, was included as negative controls.
METHODS
In this multicenter study, patients of 6 cardiothoracic centers in the Netherlands who had ≥1 PVs in situ and underwent FDG PET/CT imaging for any indication were retrospectively included. The study was approved and informed consent was waived by the local Medical Ethics Committees of all participating centers. The data, analytic methods, and study materials have been made available to other researchers for purposes of reproducing the results or replicating the procedure. 17 
Patient Identification and Selection
All patients with a PV (including percutaneously implanted valves, but excluding valvuloplasties) who underwent an FDG PET/CT scan between January 1, 2010, and March 31, 2016, were included. For all patients, at least 1 year of follow-up was available. No distinction was made between scans that were performed after first PV implantations or reimplantations.
Clinical Perspective
What Is New?
• In this large, multicenter cohort of patients who underwent 18 F-fluorodeoxyglucose (FDG) positronemission tomography/computed tomography for suspected prosthetic valve endocarditis, 2 significant confounders were identified that may have affected previous studies and, when corrected for, result in significantly improved diagnostic accuracy.
• Low inflammatory activity at the time of imaging causes false-negative interpretations, whereas prior use of surgical adhesives causes false positives.
• Previous studies reported widespread cutoffs for quantified FDG uptake because of a lack of standardization.
• In this study, a standardized cutoff of >2.0 for the ratio between FDG uptake around the affected valve and in the blood pool (standardized uptake value ratio) was 100% sensitive and 91% specific.
What Are the Clinical Implications?
• FDG positron-emission tomography/computed tomography has a high diagnostic accuracy for prosthetic heart valve endocarditis when implemented early in the diagnostic workup, and can detect prosthetic heart valve endocarditis even when blood cultures or echocardiography are negative, and before structural damage occurs.
• Additional quantitative analysis improves diagnostic accuracy and interobserver reliability, and the suggested standardized uptake value ratio cutoff of >2.0 is applicable in any center with an European Association of Nuclear Medicine Research Ltd-accredited system. • Prior use of surgical adhesives may cause falsepositive FDG uptake and needs to be taken into account.
• Physiological inflammation attributable to recent valve implantation, however, is not a reason to omit positron-emission tomography/computed tomography imaging. 
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Data Collection
Demographic and clinical data of the included patients and technical data of the included scans were entered into a collaborative database. To prevent possible confounding by follow-up scans during an active or after a previous endocarditis episode, only the first scan for suspicion of PVE was included in the analysis. No patients had undergone both a scan for suspicion of PVE and one for another (ie, oncological) indication.
Patient Data
Demographic data and the type of PVs and implantation dates, as well, were retrieved. In case of multiple replacement surgeries of the same valve, the most recent valve implantation date was used. A history of diabetes mellitus and previous endocarditis was also noted. Echocardiographic findings from the same clinical admission as the FDG PET/CT scan were recorded for the presence of vegetation (per valve), abscesses, fistulas, new dehiscence of the PV, or paravalvular leakage. If multiple echocardiograms were available, abnormalities on transesophageal echocardiography were considered leading, and, in case of multiple transesophageal echocardiographies, the reported presence of abnormal findings on one would overrule their reported absence on another to ensure an accurate reference standard and modified Duke classification.
Evidence of cardiac device or lead infection was recorded, and results of blood cultures were scored as positive if at least 1 blood culture had been positive directly before or during the clinical admission, and the causative microorganism was recorded. Results of serology and polymerase chain reaction were recorded separately. Based on these data and clinical follow-up, the modified Duke classification 2 was calculated. As a measure of inflammatory activity, C-reactive protein (CRP) and leukocyte levels were recorded if obtained close to the FDG PET/CT scan (maximum 7 days before or after the date of the scan).
Scan Data
Based on the original clinical question of the FDG PET/CT scan (derived from the report), the indication for imaging was categorized as suspicion of PVE versus other (ie, oncological) indications.
We recorded the scan date and acquisition protocol, including preparatory measures such as a fasting period of >6 hours, a low-carbohydrate diet for at least 24 hours or a heparin injection, and the administered FDG dose (in MBq), as well as the blood glucose level at the time of FDG injection, the time interval of scan acquisition after FDG injection, and whether the scanner was EARL-accredited and an EARLstandardized reconstruction was available. In case of missing images or insufficient clinical data for a reliable final diagnosis, the scan was excluded from further analyses.
Patient Classification
Patients with an FDG PET/CT scan performed for other (ie, oncological) indications were considered controls by default, because these patients had no clinical suspicion of an infection. To ensure a reliable diagnostic accuracy representative of daily clinical practice, these negative controls were primarily used for the evaluation of causes of false-positive FDG PET/CT scans, and were not included in the analysis on the diagnostic performance of PET in patients in whom PVE was suspected.
For patients who did undergo FDG PET/CT for suspicion of PVE, the final diagnosis of PVE was established through expert consensus based on all available clinical and diagnostic data, and at least 1 year of follow-up, as well. The modified Duke criteria were scored as well, 2 with the exception that echocardiographic findings unrelated to the PV were not included in the final diagnosis of PVE (eg, vegetation on 1 of the native valves would not count as a major criterion in the final Duke classification regarding PVE), and data on minor Duke criteria (eg, vascular or immunologic stigmata) were often missing.
Expert consensus was achieved through a stepwise approach in which patients were discussed by a multidisciplinary group of physicians from the Departments of Cardiology, Infectious Diseases, Medical Microbiology, Radiology, and Nuclear Medicine (the Endocarditis Team) when the diagnosis was neither confirmed by surgery/histopathology nor rejected by an uneventful 1-year followup regarding infectious disease without further antibiotic treatment.
Image Acquisition and Analysis
Depending on the center, images had originally been acquired on a Biograph mCT (Siemens Healthcare) or a Gemini TF PET/ CT (Philips Medical Systems).
Image Quality
All scans were evaluated for image quality (sharpness/noise) and classified as good, moderate, or poor by 2 independent observers. Scans that were classified as being of poor quality were excluded from further analyses. Furthermore, the quality of myocardial FDG-uptake suppression was assessed by visually comparing the maximum intensity of FDG in the myocardium to the blood pool (of the descending aorta) and the liver, and classified as I, less than blood pool; II, equal to blood pool; III, less than liver but more than blood pool; IV, more than liver; and V, intense (ie, similar to brain).
Qualitative Analysis of PVE
All images were analyzed on commercially available software (Syngo.via, Siemens) by 2 nuclear medicine physicians blinded to the original scan report and any clinical data of the patient. Each observer had several years of experience in reading FDG PET/CT scans for suspicion of PVE, device infections, and infectious diseases in general. Based on both the attenuationcorrected and noncorrected images, both observers assessed the presence of any uptake around the PV and gave a final verdict on the abnormality of this uptake (consistent with infection), taking known normal variations into account. 9 In case of disagreement, a consensus reading was performed.
(Semi)quantitative Analysis of PVE
The SUV max around the PV was measured on EARL-accredited, attenuation-corrected reconstructions. A volume of interest was defined automatically as an isocontour of 40% of the maximum measured signal intensity, which included the blood pool within and some of the soft tissue adjacent to the PV (Figure 1) . When there was a visual impression of unsuppressed myocardial FDG uptake within the automatically generated volume of interest, this area was manually removed ORIGINAL RESEARCH ARTICLE from the measurement. The SUV max was divided by the mean SUV of the blood pool in the descending aorta (at the level of the PV) to calculate the SUV ratio . This was measured within a spherical volume of interest with a maximum diameter of the lumen of the aorta (excluding the vessel wall). For all semiquantitative analyses, the average of the measurements of the 2 observers was used.
In case of multiple PVs, each valve was assessed and scored separately. Because the definition of case (PVE) versus control (no PVE) was set on a patient level rather than on a valve level, only the affected PV was included for the analyses of diagnostic performance and thresholds for SUV max and SUV ratio , to prevent erroneously classifying the scan as false-negative for the other valves. In patients with multiple valves without PVE (all negative on FDG PET/CT), the most commonly implanted valve was considered the primary valve (ie, in the following order: aortic, mitral, pulmonary, and tricuspid valve). Only the SUV max around the primary valve was included in the analysis. Scans that were not acquired on an EARL-accredited scanner or did not include an EARLaccredited reconstruction were not included in the semiquantitative analyses.
Confounders
The effect of possible confounders on the diagnostic accuracy was assessed by identification of statistically significant differences between patients with false-positive or falsenegative interpretations and those with correctly interpreted scans using a logistic regression model including all demographic and clinical variables (Table I in the online-only Data Supplement). In particular, the effect of the previously described potential positive (ie, recent valve implantation and surgical adhesives) and negative (ie, low inflammatory activity attributable to prolonged antibiotic therapy and isolated vegetation) confounders was evaluated. The effect of poor myocardial FDG-uptake suppression was evaluated both as a possible predictor of false-positive (ie, uptake that mimics an infectious pattern) and false-negative (ie, diffuse myocardial uptake that masks an underlying infectious pattern) scans. Subsequently, all patients or scans with statistically significant predictors of a negative or positive confounding effect were excluded to evaluate possible improvement of diagnostic accuracy.
Statistics
Accuracy of FDG PET/CT for the diagnosis of PVE was assessed by comparing the final imaging diagnosis (based on visual analysis) with the reference standard of expert consensus based on all available clinical data. For comparisons between groups, the Student t test or Mann-Whitney U test was used for normally distributed and nonparametric data, respectively. For all statistical analyses, a significance level of α=0.05 and 95% CIs were used. SPSS v25.0 (IBM Corp) was used for all analyses, with the exception of CIs for C-statistics, for which MedCalc v18.2.1 (MedCalc Software) was used. Unless otherwise indicated, the interquartile range or CI is denoted in square brackets. Fused PET/CT (1) and PET (2) images. A, Horizontal view of a measurement of the SUV max around the PV by using an automated volume of interest based on an isocontour (red line) encompassing all voxels with an intensity of at least 40% of the voxel with the highest intensity in the spherical selected area (red ellipse). B, Coronal view of a measurement of the mean SUV in the blood pool of the descending aorta using a small spherical volume of interest (blue circle), drawn with particular care not to include the aortic wall. C, Combined sagittal view of both measurements. The SUV ratio is calculated by dividing the SUV max around the PV by the mean SUV in the blood pool: 6.97/2.27=3.07. FDG indicates 18 F-fluorodeoxyglucose; PV, prosthetic heart valve; PVE, prosthetic heart valve endocarditis; SUV max , maximum standardized uptake value; and SUV ratio , standardized uptake value ratio.
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The interobserver agreement on quantitative analyses was evaluated by using an absolute-agreement 2-way mixed intraclass correlation coefficient. 18 Receiver-operator curves were used to analyze diagnostic distinctiveness (as area under the curve, AUC), and the optimal cutoff values for both SUV max and SUV ratio were determined by using the Youden J statistic, assuming that sensitivity and specificity are equally important. Outcomes of the quantitative analyses were adjusted for the same confounders identified in the visual assessment through exclusion of the same scans.
RESULTS
Patient Characteristics
Between January 2010 and March 2016, 390 FDG PET/ CT scans had been acquired in 289 patients with at least 1 PV. After exclusion of scans that were irretrievable, that had a poor image quality, or for which sufficient clinical data were lacking, and after exclusion of all follow-up scans, 237 FDG PET/CT scans remained ( Figure 2 ).
One hundred sixty scans were performed for suspicion of PVE, whereas 77 scans were acquired for other, mostly oncological indications. Clinical parameters including blood cultures and results of echocardiography at the time of these scans are listed in Table 1 . Of the 160 patients in whom PVE was suspected, 80 had a final diagnosis of PVE, whereas the other 80 were deemed not to have PVE.
Acquisition Parameters and Image Quality
Acquisition parameters of the 237 FDG PET/CT scans are shown in Table II in the online-only Data Supplement. Overall image quality was good in 161 and moderate in 76 scans. All patients had fasted for at least 6 hours, whereas 88 of the patients in whom PVE was suspected (55%) had also been on a low-carbohydrate diet for at least 24 hours before FDG injection, of whom 20 (12%) had additionally received a heparin injection (50 IU/kg) 15 minutes before the FDG injection. One patient in the negative control group who underwent FDG PET/CT for suspicion of cardiac sarcoidosis had also been on a lowcarbohydrate diet for >24 hours.
The preparatory low-carbohydrate diet (n=88) significantly reduced the average grade of physiological 
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Circulation. Diabetes mellitus, n (%) 23 (14) 10 (13) 13 (16) 18 (23) Prior history of endocarditis, n (%) 33 (21) (8) 6 (7) 6 (8) 6 (8) Pulmonary 14 (9) 13 (16) 
Primary valve type, § n (%) 
Including replacement of ascending aorta (ie, Bentall), n (%) 21 (13) 15 ( 
Visual Assessment
Visual assessment of FDG uptake by 2 independent blinded observers resulted in 66 positive and 171 negative PET/CT scans. After a consensus reading of 23 scans (10%), there were no remaining discrepancies between the 2 observers in the evaluation of pathological FDG uptake.
In the 160 PET/CT scans performed for suspicion of PVE, PET was positive in 59 of the 80 patients with PVE, and negative in 74 of 80 patients without PVE. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of scans acquired for suspicion of PVE, without any correction, were 74%, 91%, 89%, and 78%, respectively. When
Haemophilus parainfluenzae F-fluorodeoxyglucose; IQR, interquartile range; MV, mitral valve; n/a, not available; PCR, polymerase chain reaction; PET, positron-emission tomography; PHV, prosthetic heart valve; PV, pulmonary valve; PVE, prosthetic heart valve endocarditis; TAVI, transcatheter aortic valve implantation; and TV, tricuspid valve.
*Final diagnosis based on surgical findings (if reoperated), expert opinion, and follow-up. †Statistically significantly different from the scans performed for other indications (P<0.05, calculated for all scans for suspicion of PVE). ‡Statistically significantly different from the PVE group (P<0.05, only calculated for no-PVE groups). §The primary valve was defined as either the valve involved in, or suspected of, PVE, or in case of controls, based on the order of most common occurrence (AV, MV, PV, TV).
║Percentages of abnormal echocardiographic findings are relative to the number of available echocardiograms. ¶Three patients had a vegetation on both their prosthetic AV and their prosthetic MV. #The MV vegetation was deemed a remainder of previous endocarditis, whereas the pulmonary and tricuspid vegetation were later concluded to have probably been small thrombi. The 1 abscess found in a patient concluded not to have PVE was found to be a remainder of previous endocarditis before PHV implantation, because it had decreased in size in comparison with imaging before surgery. Four pre-existing paravalvular leakages were found in this control group. **Two patients were deemed to have both PVE and a cardiac implantable electric device infection. One patient was concluded to have a pacemaker lead infection but not PVE, based on the absence of abnormalities on echocardiography, CT angiography, and PET/CT.
† †For blood cultures, PCR, and serology, even if they were no longer positive at the time of FDG PET/CT imaging, these were classified as positive if they had been positive during the clinical episode preceding the scan. ‡ ‡In 2 patients, blood cultures were not performed or data about these could not be retrieved from the electronic patient file. § §HACEK: Haemophilus species, Aggregatibacter (Actinobacillus) species, Cardiobacterium hominis, Eikenella corrodens, Kingella species. ║║Formerly known as Proprionibacterium. ¶ ¶Only PCRs and serologies that newly identified a causative micro-organism are reported. 1 ). In 24 of the 27 cases of PVE in which echocardiography was negative, the FDG PET/ CT scan was positive. Thus, when adding FDG PET/ CT to the diagnostic workup, the combined sensitivity increased to 96%. Of the 53 patients deemed not to have PVE for whom an echocardiogram report was available, echocardiography showed signs of endocarditis in 8 (specificity 85%). None of them had a positive FDG PET/CT scan (combined specificity 100%).
False-Negative Interpretations
Overall, 21 scans of patients with PVE (26%) were false-negative based on the visual analysis. Fourteen of these patients had a definite diagnosis of PVE according to the modified Duke criteria, whereas 7 had a possible PVE classification.
As a measure of inflammatory activity, the average CRP at the time of PET imaging was lower in these 21 patients than in those with a true positive scan (25.0±24.5 versus 73.7±59.9 mg/L; P=0.001). At the time of these 21 scans, 17 patients (81%) had a CRP of <40 mg/L (4× upper normal limit), which was a statistically significant predictor of a false-negative FDG PET/CT scan (P=0.016, Figure 3A ). When excluding all 69 scans of patients with a CRP of <40 mg/L at the time of imaging (n=91), the sensitivity, specificity, PPV, and NPV of visual PET analysis for PVE (in patients with a CRP of >40 mg/L) improved to 91%, 91%, 91%, and 91%, respectively. None of the other variables (including leukocyte levels at the time of imaging) were significant predictors of a false-negative 2) and maximum-intensity PET (3) projections. A, An 80-year-old male patient with definite Enterococcus faecalis PVE of a biological aortic PV, who had already been treated with antibiotics for 65 days before FDG PET/CT imaging (CRP was 14 mg/L), and despite a negative scan (SUV ratio 1.68), was reoperated 5 days later because of persisting vegetation with new septic emboli. PVE was intraoperatively macroscopically and subsequently histopathologically confirmed. B, A 57-year-old male patient with a biological aortic valve and ascending aorta replacement (Bentall procedure) who underwent FDG PET/CT imaging for oncological indications (myocardial suppression was good, possibly thanks to prolonged >12-hour fasting), showing intense uptake of FDG (SUV ratio 6.78) in the areas where surgical adhesives had been applied, particularly surrounding the distal seam of the ascending aortic graft. C, A 46-year-old male patient with a mechanical aortic valve who underwent FDG PET/CT imaging for suspicion of PVE, but in whom PVE was ruled out by negative blood cultures, negative echocardiography, and an alternative diagnosis of upper urinary tract infection, showing circular FDG uptake (C3, SUV ratio 3.66) in the basal septal and anterior myocardial wall (C2), which could have been mistaken for a sign of periannular infection (C1), but was most likely caused by insufficient adherence to the low-carbohydrate diet. CRP indicates C-reactive protein; CT, computed tomography; FDG, 18 F-fluorodeoxyglucose; PET, positronemission tomography; PV, prosthetic heart valve; PVE, prosthetic heart valve endocarditis; and SUV ratio , standardized uptake value ratio. Of the 4 patients with a false-negative visual interpretation of their FDG PET/CT scan despite higher CRP levels, 3 had an isolated vegetation on their aortic PV without any signs of structural damage to the periannular tissue. The fourth patient with a false-negative FDG PET/CT had negative blood cultures, but was deemed to have PVE by expert consensus because of echocardiographic signs of a periannular extension, for which, however, the patient was not reoperated because of a too high estimated procedural risk. Thus, absolute certainty about the diagnosis of PVE in these patients could not be achieved, but they were all pragmatically antibiotically treated for at least 6 weeks despite a negative FDG PET/CT scan.
False-Positive Interpretations
Six scans in patients in whom PVE was suspected but who had a final rejected diagnosis (8%) were falsepositive.
In 3 of these patients, the surgical report of the PV implantation mentioned use of surgical adhesives (ie, BioGlue [CryoLife Inc]), which was the only statistically significant predictor of a false-positive scan in the logistic regression model. The area of increased FDG uptake was consistent with the description of the area the surgical adhesive had been applied to in the surgical report of all 3 patients ( Figure 3B ). There were no negative scans in patients in whom the use of surgical adhesives had been reported (n=4). Excluding scans affected by this confounder increased the specificity and PPV of PET in patients in whom PVE was suspected to 96% (74/77) and 95% (58/61), respectively.
In 2 other patients, the PV had been implanted 11 and 18 days before FDG PET/CT imaging, respectively. However, 16 other patients who underwent imaging within 1 month of PV implantation had a true-negative FDG PET/ CT scan. Overall, in 20 patients, the PV had been implanted <1 month before FDG PET/CT imaging, with only 2 false-positive FDG PET/CT scans (10%). Two other patients with an implantation this shortly before FDG PET/CT imaging were deemed to have PVE: 1 scan was true positive, and the other was false negative. Twenty-seven scans had been acquired in patients with a PV implantation between 1 and 3 months before imaging, with only 2 false-positive FDG PET/CT scans in this group as well (7%). One of these false positives within 1 to 3 months after surgery was also attributed to the use of BioGlue, bringing the total number of false-positive scans in patients with a PV implantation <3 months before FDG PET/CT imaging to 3 of 47 (6%). Neither the number of days since PV implantation, nor an implantation within 1 or 3 months, were significant predictors of a false-positive scan.
In the last patient in whom PVE was suspected who had a false-positive scan, and in the 1 patient with a false-positive scan that had been acquired for oncological indications, as well, myocardial FDG uptake had been classified by both observers as more than liver and intense, respectively, which may have hampered the visual assessment ( Figure 3C ). Neither patient had been prepared by means of a low-carbohydrate diet. However, because poor myocardial suppression occurred in many more correctly evaluated FDG PET/CT scans, this was not a statistically significant confounder either.
Diagnostic Performance Adjusted for Significant Confounders
Following the exclusion of scans influenced by low inflammatory activity at the time of imaging and those influenced by prior use of surgical adhesives, the sensitivity, specificity, PPV, and NPV of FDG PET/CT in patients in whom PVE was suspected increased to 91%, 95%, 95%, and 91%, respectively. Recent valve implantation (within 1 or within 3 months before FDG PET/CT imaging) was not a significant confounder.
Quantitative Analysis
Of the 237 included scans, 170 had an EARL-accredited reconstruction available for (semi)quantitative analyses: 55 in the PVE group and 115 in the control groups. The mean SUV max and SUV ratio (average of both observers) in the PVE group were significantly higher than in both the group of patients in whom PVE was suspected with a final rejected diagnosis and the negative control group (Table 2, Figure 4) .
A total of 52 EARL-standardized scans (10 in the PVE group, 14 in the no-PVE after suspicion group, and 28 in the negative control group) were affected by unsuppressed myocardial FDG uptake in such a way that 1 or both observers had indicated that this may have influenced their measurements. However, excluding these scans from the analyses did not substantially change the average values in any of the groups. When excluding scans that may have been confounded by either low inflammatory activity (CRP<40 mg/L) or prior use of surgical adhesives, the differences between the PVE group and the no-PVE groups increased (Table 2, Figure 4 ). In particular, 2 scans with very high values because of surgical adhesives were removed from the control group by this correction. There were no significant differences in SUV max or SUV ratio between the patients in whom PVE was initially suspected with a rejected diagnosis and those who underwent FDG PET/CT imaging for other indications.
Only looking at EARL-standardized scans obtained for suspicion of PVE (n=111) and assuming sensitivity and Figure 5B ). Adjusted for confounders, a SUV ratio of 2.6 had a specificity (and PPV) of 100% for PVE ( Figure 5B ).
When verifying these cutoff values in the negative control group without any suspicion of PVE, 4 of 59 scans had an SUV ratio of >2.0 (specificity 93%), whereas F-fluorodeoxyglucose; PV, prosthetic heart valve; PVE, prosthetic heart valve endocarditis; SUV max , maximum standardized uptake value; and SUV ratio , standardized uptake value ratio.
*Final diagnosis based on surgical findings (if reoperated), expert opinion, and follow-up. †Significantly lower than the average measurements in the PVE group. ‡Excluding measurements that were indicated as having possibly included unsuppressed myocardial FDG uptake by both observers (n=52, Table III in the online-only Data Supplement).
§Excluding scans of patients in whom CRP was <40 mg/L at the time of imaging or surgical adhesives had been used during PV implantation.
Figure 4. Differences in SUV max and SUV ratio between the PVE and no-PVE groups.
Box plots for the 2-observer average measured SUV max (Left) and SUV ratio (Right) in cases (red) and controls (green) in all EARL-standardized scans acquired for suspicion of PVE (n=111), and †after exclusion of scans in patients with low inflammatory activity (CRP<40 mg/L) at the time of imaging or reported use of surgical adhesives during PV implantation (n=64). CRP indicates C-reactive protein; EARL, European Association of Nuclear Medicine Research Ltd; PV, prosthetic heart valve; PVE, prosthetic heart valve endocarditis; SUV max , maximum standardized uptake value; and SUV ratio , standardized uptake value ratio. *Final diagnosis based on surgical findings (if reoperated), expert opinion, and follow-up. ‡Significantly different from adjacent PVE group (P<0.001).
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none were >2.6. Three of these 4 measurements had been done in oncological scans with intense myocardial uptake because of a lack of adequate patient preparation, which may have influenced these measurements. The fourth had a SUV ratio of 2.1.
Interobserver Variability
Overall, in the EARL-standardized scans (n=170), the differences between SUV max and SUV ratio measurements of both observers were relatively small (mean SUVmax difference -0.04; 95% CI, -0.35 to 0.28; P=0.82; mean SUV ratio difference 0.04; 95% CI, -0.16 to 0.25; P=0.70). The 2-way mixed intraclass correlation coefficient of absolute agreement for single SUV max measurements (0.82; 95% CI, 0.76-0.86) and SUV ratio measurements (0.84; 95% CI, 0.78-0.88) indicated a good-to-excellent agreement between the observers on both variables. Excluding scans with unsuppressed myocardial FDG uptake that may have hampered these measurements increased interobserver reliability to excellent for both variables, with intraclass correlation coefficients of 0.94 (95% CI, 0.91-0.96) and 0.95 (95% CI, 0.92-0.96) for SUV max and SUV ratio , respectively.
DISCUSSION
To our knowledge, this multicenter study reports the largest patient cohort on the diagnostic performance of FDG PET/CT in PVE to date, including a negative control group of patients with a PV who underwent FDG PET/ CT imaging for other indications than suspected PVE.
Although several authors have reported the possible influence of prolonged antibiotic therapy and surgical adhesives, to our knowledge, this study is the first to identify these factors as significant confounders and to assess the true diagnostic accuracy of FDG PET/CT by excluding scans that were affected by them. Finally, in this study, standardized quantification of FDG uptake after exclusion of these confounders allowed for identification of a reliable diagnostic cutoff for PVE that can be used in any center with an EARL-calibrated scanner (currently >150 centers in Europe 16 ). The diagnostic performance of the visual assessment of FDG PET/CT scans in patients in whom PVE was suspected in our study, not adjusted for confounders, was reasonable and comparable to previous studies 12, 19 , with a sensitivity, specificity, PPV, and NPV of 74%, 91%, 89%, and 78%, respectively. As previously mentioned, low inflammatory activity at the time of FDG PET/CT imaging and prior use of surgical adhesives during PV implantation were identified, respectively, as significant predictors of false-negative or false-positive misinterpretations in a logistic regression model. Excluding scans affected by these 2 significant confounders significantly improved the diagnostic performance values of the visual assessment in patients in whom PVE was suspected to 91%, 95%, 95%, and 91%.
Confounding Factors
Low Inflammatory Activity Several authors of previous studies regarding FDG PET/ CT in suspected PVE have suggested the influence of F-fluorodeoxyglucose; PET/CT, positron-emission tomography/computed tomography; PV, prosthetic heart valve; PVE, prosthetic heart valve endocarditis; ROC, receiver-operator curve; sens, sensitivity; spec, specificity; SUV max , maximum standardized uptake value; and SUV ratio , standardized uptake value ratio. ORIGINAL RESEARCH ARTICLE low inflammatory activity, measured by CRP or white blood cell count, or prolonged antibiotic therapy on false-negative PET interpretations. 8, 19 However, no studies to date had corrected for this confounder, even though several studies on the value of FDG PET/CT for the detection of infections of unknown origin have shown that high inflammatory activity is a significant predictor of, and may be a requirement for, an adequate FDG PET/CT scan. 20, 21 The drastic increase in sensitivity observed when adding FDG PET/CT to echocardiography (from 65% of echocardiography alone to 96% of both imaging techniques combined), without even adjusting for low inflammatory activity, is probably caused by the fact that the patients with negative echocardiograms are often also the patients that were scanned early in the disease process, before structural damage or vegetation ensued. It is in these patients that levels of inflammatory activity are still high and that FDG PET/CT is most reliable.
Whether initial or empirical antibiotic therapy should be ceased for diagnostic purposes, however, in case inflammatory parameters have already diminished without a certain diagnosis, remains questionable in light of the risks associated with unsuccessfully treated PVE. In our opinion, a pragmatic antibiotic treatment of a possible PVE is preferable over a PET-confirmed definite PVE that has to be reoperated because of the cessation of antibiotic therapy. Although a CRP level of <4 times the upper normal limit (<40 mg/L) was a significant and major predictor of false-negative interpretations in this study, FDG PET/CT may still be considered when inflammatory parameters are low if the diagnosis of PVE has significant therapeutic consequences. In our study, FDG PET/CT was positive in 13 of 28 (46%) patients with a CRP of <40 mg/L and a definite diagnosis of PVE.
Surgical Adhesives
Surgical adhesives are known to be very FDG avid, with several case reports on patients who underwent lung surgery, aortic surgery, or heart valve surgery showing intense FDG uptake in areas where they had been applied, which can persist for several years if not indefinitely. 9 In our study, we evaluated the surgical reports of all patients, of which 4 mentioned the use of a surgical adhesive during PV implantation. All 4 of these patients (3 without PVE, 1 with PVE) had a positive FDG PET/CT scan, and, as far as could be determined from the surgical report, the areas of FDG uptake were consistent with the areas that these adhesives had been applied to.
Recent Valve Implantation
Current European Society of Cardiology (ESC) guidelines recommend not to perform FDG PET/CT within 3 months of PV implantation. 4 The reasoning behind this 3-month grace period was the assumed likelihood of false-positive findings attributable to sterile inflammation, as seen in recent lung cancer resection surgery, 22 based on expert opinion and a case report of increased FDG uptake around a biological mitral PV implanted 2 months before FDG PET/CT imaging. In the largest study on FDG PET/CT in suspected PVE before the 2015 update of the ESC guidelines, Saby et al 19 excluded patients with a PV implanted <1 month before admission to avoid false-positive results related to early postoperative inflammation. They also referred to the same case report, but described no false positives that could have been attributed to PV implantation between 2 and 3 months before imaging. In another study by Rouzet et al, 23 in which FDG PET/CT was compared with radiolabeled leukocyte scintigraphy in patients in whom PVE was suspected, 6 patients in whom a PV had been implanted <2 months before imaging had a false-positive FDG PET/CT result, whereas leukocyte scintigraphy was not affected by this sterile inflammation. Since the publication of this study and the 2015 update of the ESC guidelines, however, several studies that included patients scanned within 3 months of implantation, some even within 2 weeks, have explicitly described true-negative findings. 11 Moreover, Mathieu et al 24 recently described a cohort of 51 patients without PVE, and showed that the mean amount of FDG uptake was not significantly different between patients scanned within 3 months of implantation or thereafter, and that elevated FDG uptake may occur as late as 8 years after PV implantation without any clinical suspicion of PVE. In our study, recent valve implantation was not a significant predictor of false-positive interpretations, and we cannot substantiate the ESC guideline recommendation. We believe performing FDG PET/CT early after surgery poses no significant diagnostic difficulties based on our findings and the evidence available from previous studies.
Myocardial FDG Uptake
Visual assessment of FDG uptake around the PV was not significantly hampered by unsuppressed myocardial uptake in this study, even though the myocardial uptake had been classified as more than liver or intense in a substantial number of scans. In particular, in patients who had not been prepared with a low-carbohydrate diet before the scan, myocardial FDG uptake was frequently intense. Unsuppressed myocardial FDG uptake did not hamper the quantitative measurements as much as we had initially anticipated, either, as demonstrated by the merely slight change in average SUV max and SU-V ratio when excluding scans with myocardial uptake that may have possibly affected the observers' measurements. However, it did significantly decrease interobserver reliability, and should always be minimized as much as possible by using at least a >6-hour fast (in our own experience, preferably at least 12 hours) and a 24- 
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hour low-carbohydrate diet to allow for easy distinction of periprosthetic FDG uptake. 10, 15 An additional intravenous injection of 50 IU/kg of unfractionated heparin 15 minutes before FDG administration (on top of the prolonged fasting and low-carbohydrate diet) slightly further reduced myocardial FDG uptake (Table III in the online-only Data Supplement), but the sample size was too small to show a clinically meaningful difference, and the small potential additional benefit of this should always be weighed against the possible adverse effects. [25] [26] [27] Without a low-carbohydrate diet or extensive fasting (>18 hours), however, the additional value of intravenous heparin seems limited and does not result in sufficient myocardial suppression. 28 Furthermore, patients already on low-molecular-weight heparin or warfarin therapy most likely already benefit from the incremental suppression that these drugs provide, and do not need an additional unfractionated heparin bolus injection.
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Quantitative Analysis
Quantification of FDG uptake, expressed as SUV max or SUV ratio , showed reasonable diagnostic performance with an AUC for SUV max of 0.81 and an AUC for SUV ratio of 0.83, but lacked sufficient sensitivity. However, after exclusion of the previously mentioned significant confounders, the diagnostic performance drastically increased, and more reliable cutoffs could be identified.
Pizzi et al 12 reported an AUC for SUV max and SUV ratio of 0.89 in a prospective study comprising 92 patients in whom PVE was suspected, with a sensitivity/specificity for their cutoffs (SUV max ≥3.7, SUV ratio ≥1.69) of 91%/79% and 91%/76%, respectively. Their measurements had not been performed on EARL-standardized reconstructions. After exclusion of scans affected by confounders, we found slightly different cutoffs for both measures (SUV max ≥3.3, SUV ratio ≥2.0) with a sensitivity/specificity of 97%/79% and 100%/91%, respectively. SUV ratio was the most reliable and predictive measure, possibly because it was less dependent on patient characteristics and scanning parameters, with a 91% PPV for a SUV ratio of ≥2.0 and a 100% PPV for a SUV ratio of ≥2.6.
As a confirmation of validity, there were no significant differences in measured SUV max or SUV ratio between the group of patients in whom PVE was initially suspected with a final rejected diagnosis and the negative control group of patients who underwent FDG PET/CT imaging for other indications.
Some authors have suggested calculating the SUV ratio by dividing by the mean SUV in the atrial or mediastinal blood pool (as opposed to the blood pool in the descending aorta) because some patients may show increased FDG uptake in the aortic wall because of aortic calcifications or active plaque. 13, 14 In our study, we took particular care not to include the vessel wall in the volume of interest in the descending aorta, and preferred to adhere to the most commonly used measurement method for comparison. 10 In addition, in case of valvular regurgitation or atrial fibrillation, the atrial wall may similarly show increased FDG uptake.
Interobserver Reliability
Interobserver agreement for quantitative measurements of FDG uptake was good to excellent in our study, and significantly improved when excluding scans with poorly suppressed myocardial FDG uptake. This shows that quantification of perivalvular FDG uptake is a reliable tool with diagnostic cutoff values applicable to all centers with EARL accreditation, which allows for less-subjective image evaluation. There were, however, some discrepancies between the observers in the initial visual assessment of a number of scans (10%), for which a consensus reading was performed. In the majority of these, experience with normal variations of perivalvular uptake, which 1 observer arguably had less than the other, was key to a correct interpretation, exemplifying that the visual assessment of paravalvular FDG uptake is not always black and white and probably subject to a learning curve. Although the exact role of the pattern and distribution of FDG uptake around a PV (eg, heterogeneous, diffuse, or focal) is still unclear, some patterns such as diffuse, slightly increased FDG uptake have been attributed to physiological inflammation processes around the PV.
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Limitations
Our study had a number of potential limitations. Most importantly, besides the regular limitations of a retrospective study design, our study may have been influenced by the availability of the FDG PET/CT results to the expert team determining the final diagnosis, which may have introduced an incorporation bias. This is, however, the case in all studies to date regarding novel imaging techniques for suspected PVE, and is hard to circumvent. Even when investigators are blinded to the FDG PET/CT results, the subsequent clinical course of action will usually reveal the implications that the FDG PET/ CT findings had. Ideally, although imaginably difficult and possibly unethical to realize, the diagnostic performance of FDG PET/CT would be evaluated in a prospective trial in which even the physicians remain blinded to its findings. In addition, although we strongly believe that FDG PET/CT may aid in the timely diagnosis of PVE, the impact of an early diagnosis of PVE by FDG PET/CT on morbidity and mortality remains uninvestigated, and would require large randomized controlled trials to be elucidated.
Next, all FDG PET/CT scans were reassessed by 2 independent observers with several years of experience ORIGINAL RESEARCH ARTICLE in FDG PET/CT imaging of suspected PVE, who were blinded to all clinical data. The external validity of a fully blinded assessment of FDG PET/CT in suspected PVE could be contested, because clinical information is often important for the interpretation of possibly pathological FDG uptake. In clinical practice, results of the FDG PET/CT scan would be interpreted in a multidisciplinary setting in the context of the clinical presentation, microbiological and echocardiographic findings, and the results of other imaging techniques, as well, such as CT angiography. Furthermore, the blinding may have been imperfect in the presence of obvious findings such as large malignancies, biasing the interpretation by revealing an alternate diagnosis, especially because the observers were aware of our study design. This bias did not, however, have any effect on the calculation of diagnostic accuracy in our study, because oncological scans were not included in these analyses.
Finally, the exclusion of scans affected by significant confounders may have limited the clinical applicability and generalizability of our findings. However, the confounders identified in this study can most likely be identified and mitigated in clinical practice as well, most importantly by implementing FDG PET/CT early in the diagnostic workup of PVE to prevent imaging after extended periods of antibiotic therapy, while insight in the surgical report may help to identify increased FDG uptake attributable to use of surgical adhesives.
Clinical Implications
Our findings may have several important clinical implications. First, our study shows that FDG PET/CT should Figure 6 . Flowchart for the proposed diagnostic workup of suspected PVE. CAD indicates coronary artery disease; CAG, coronary angiography; CRP, C-reactive protein; CT, computed tomography; CTA, computed tomography angiography; FDG, 18-fluorine fluorodeoxyglucose; IE, international units; MRI, magnetic resonance imaging; NAC, nonattenuation corrected reconstructions; PCR, polymerase chain reaction; PET/CT, positron-emission tomography/computed tomography; PHV, prosthetic heart valve; PVE, prosthetic heart valve endocarditis; SUV ratio , standardized uptake value ratio; TOE, transesophageal echocardiography; and TTE, transthoracic echocardiography.
F-FDG PET/CT in Prosthetic Valve Endocarditis October 2, 2018
ORIGINAL RESEARCH ARTICLE
preferably be implemented early in the diagnostic workup of suspected PVE to prevent the negative confounding effect of low inflammatory activity, ideally while CRP levels are >40 mg/L ( Figure 6 ). Moreover, if implemented early, FDG PET/CT can detect PVE before structural damage occurs, allowing timely appropriate antibiotic treatment that could possibly prevent a reoperation, while also preventing missed diagnoses because echocardiography may be negative in these early stages of the disease. 10 In any patient with a PV and positive blood cultures, particularly if the micro-organism is known to be aggressive (eg, Staphylococcus aureus), 30 FDG PET/CT should readily be considered in the absence of clear alternative diagnoses. Second, if performed in a timely manner, and taking into account possible confounders, EARL-standardized quantification of FDG uptake around PVs (as SUV ratio ) has a very high predictive value for PVE at a cutoff of ≥2.0 (100% sensitivity, 91% specificity), which can immediately be applied in daily clinical practice in all EARL-accredited centers. Third, the interpreting nuclear physician has to be explicitly made aware of prior use of surgical adhesives during PV implantation. Fourth, although myocardial FDG uptake did not substantially influence our results, adequate suppression by at least a low-carbohydrate diet is essential for reliable PV assessment, and easy to achieve. And finally, our results do not corroborate ESC guideline recommendations to avoid FDG PET/CT in patients with a recently implanted PV. The possibility of periprosthetic FDG uptake because of physiological inflammation should always be taken into account, although future studies on the distribution and patterns of FDG uptake may identify characteristics that further aid the distinction between inflammation and infection. Most importantly, however, the goal should never be to replace routine PVE diagnostics (eg, echocardiography, blood cultures, computed tomography angiography), but rather to combine all these modalities, each with their specific strengths and weaknesses, to achieve optimal diagnostic accuracy ( Figure 6 ).
CONCLUSIONS
Both visual and quantitative assessment of FDG PET/CT have a high diagnostic accuracy in patients in whom PVE is suspected when implemented early in the diagnostic workup to prevent the negative confounding effect of low inflammatory activity (eg, because of prolonged antibiotic therapy). As a quantitative measure of FDG uptake, an EARL-standardized SUV ratio of ≥2.0 is a 100% sensitive and 91% specific predictor of PVE. Recent valve implantation did not significantly influence the diagnostic performance of FDG PET/CT in our study, but surgical adhesives used during implantation did.
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